Cancer | Targin Cancer Pain

Cancer research study

What is the primary objective of this study?

To Determine the Safety and Efficacy of Oxycodone / Naloxone Prolonged Release Tablets compared to Oxycodone PR in Subjects with Moderate to Severe, Chronic Cancer Pain

Who is eligible to participate?

Inclusion 1. Males

Which medical condition, disease, disorder, syndrome, illness, or injury is researched?



Study Interventions

Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.



Study Arms

Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.

Oxycodone/Naloxone5/2.5mg, 10/5mg, 20/10mg or 40/20mg

Oxycodone5mg, 10mg, 20mg or 40mg

Study Status


Start Date: June 1, 2013

Completed Date: December 30, 2015

Phase: Phase 3

Type: Interventional


Primary Outcome: BFI-Bowel Function Index

Secondary Outcome: BPI-Brief Pain Index

Study sponsors, principal investigator, and references

Principal Investigator: Victoria Yu

Lead Sponsor: Mundipharma (China) Pharmaceutical Co. Ltd


More information:

Discuss Oxycontin